Stay updated with breaking news from Teva Pharms. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Federal Circuit denied a petition for en banc review of a panel opinion finding induced infringement liability despite the manufacturer’s adherence to skinny labeling rules, and suggested equitable estoppel was the appropriate vehicle. GlaxoSmithKline LLC v. Teva Pharms
US Court of Appeals for the Federal Circuit upheld a finding that patents covering Narcan, a naloxone-based intranasal opioid overdose treatment, were obvious despite evidence of long-felt need.
The US Court of Appeals for the Federal Circuit upheld a finding that patents covering Narcan, a naloxone-based intranasal opioid overdose treatment, were obvious despite evidence of...
The US Court of Appeals for the Federal Circuit denied a generic drug manufacturer’s petition for en banc review of a panel opinion finding induced infringement liability despite the...
The US District Court for District of Delaware granted the plaintiff’s motion to exclude defendant’s expert testimony for being based on an erroneous legal theory in a suit alleging defendants’ generic ANDA product would infringe Exela’s patents under the Hatch-Waxman Act.